JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1991; 17:391-396
© 1991 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kavanagh, K.
Right arrow Articles by Mitchell, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kavanagh, K.
Right arrow Articles by Mitchell, L.

Drug therapy for ventricular tachyarrhythmias: how many electropharmacologic trials are appropriate?

KM Kavanagh, DG Wyse, HJ Duff, AM Gillis, RS Sheldon, and LB Mitchell

Department of Medicine, Foothills General Hospital, Calgary, Alberta, Canada.

To determine how many electropharmacologic drug trials should be performed to select therapy for patients with ventricular tachyarrhythmias, the outcome of 150 consecutive patients with inducible ventricular tachyarrhythmias undergoing serial electropharmacologic testing was examined. The probability of identifying predicted effective therapy (inductive of fewer than five ventricular responses with three ventricular extrastimuli at three pacing cycle lengths) and the probability of that therapy preventing sustained ventricular tachyarrhythmia recurrences were determined as a function of the number of preceding trials. The probability ( +/- SE) of identifying predicted effective therapy by the first trial (0.23 +/- 0.03) was significantly higher than that of the second (0.09 +/- 0.04), third (0.08 +/- 0.04) and fourth (0.05 +/- 0.04) trials (p = 0.001). No patient had predicted effective therapy identified by subsequent trials. The 2 year actuarial probability of freedom from sustained ventricular tachyarrhythmias on predicted effective therapy was higher for the first (0.79 +/- 0.08), second (0.73 +/- 0.13) and third (0.86 +/- 0.13) trials than for the fourth (0.33 +/- 0.27) trial (p = 0.02). Thus, the probability of selecting therapy with long-term efficacy was highest for the first trial (0.18), intermediate for the second (0.07) and third (0.07) trials and lowest for the fourth (0.02) and subsequent (0.00) trials. Accordingly, the electropharmacologic approach to therapy selection should be abandoned after three unsuccessful trials.


This article has been cited by other articles:


Home page
 CirculationHome page
K. L. Lee, G. Hafley, J. D. Fisher, M. R. Gold, E. N. Prystowsky, M. Talajic, M. E. Josephson, D. L. Packer, A. E. Buxton, and for the Multicenter Unsustained Tachycardia Trial
Effect of Implantable Defibrillators on Arrhythmic Events and Mortality in the Multicenter Unsustained Tachycardia Trial
Circulation, July 9, 2002; 106(2): 233 - 238.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. G. Wyse, M. Talajic, G. E. Hafley, A. E. Buxton, L. B. Mitchell, T. K. Kus, D. L. Packer, W. H. Kou, R. Lemery, P. Santucci, et al.
Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): drug testing and as-treated analysis
J. Am. Coll. Cardiol., August 1, 2001; 38(2): 344 - 351.
[Abstract] [Full Text] [PDF]

Home page
 JWatch GeneralHome page
HOW MANY ELECTROPHYSIOLOGIC STUDIES ARE ENOUGH
Journal Watch (General), February 22, 1991; 1991(222): 4 - 4.
[Full Text]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1991 by the American College of Cardiology Foundation.